IGF1R and breast carcinoma: Kruger et al., also reported that IGF-1R activation rather than IGF-1R overexpression is sufficient to induce downstream activation of the MAPK/PI3K signalling pathways and overcome tamoxifen treatment in breast cancer (Kruger et al., 2020).